Xilio Therapeutics, Inc. (XLO): Total Liabilities
$119.41M
As of 2025-12-31
$81.99M
As of 2026-06-30
+52.7%
3-year compound annual growth
+23.5%
5-year compound annual growth
| Period ended | Total Liabilities | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $119.41M | +123.3% | 2026-03-23, Balance as of period end |
| 2024-12-31 | $53.48M | +121.9% | 2026-03-23, Balance as of period end |
| 2023-12-31 | $24.10M | -28.1% | 2025-03-11, Balance as of period end |
| 2022-12-31 | $33.52M | +2.7% | 2024-04-01, Balance as of period end |
| 2021-12-31 | $32.63M | -21.6% | 2023-03-02, Balance as of period end |
| 2020-12-31 | $41.60M | n/a | 2022-03-01, Balance as of period end |
Total Liabilities at similar companies
| Company | Year ended | Total Liabilities | Change YoY |
|---|---|---|---|
| Xilio Therapeutics, Inc. (XLO) | 2025-12-31 | $119.41M | +123.3% |
| Integrated Biopharma Inc (INBP) | 2026-06-30 | $7.67M | +67.3% |
| Cumberland Pharmaceuticals Inc (CPIX) | 2025-12-31 | $52.28M | -1.4% |
| Aquestive Therapeutics, Inc. (AQST) | 2025-12-31 | $194.09M | +20.1% |
| Wave Life Sciences, Inc. (WVE) | 2025-12-31 | $112.27M | -16.7% |
| Biofrontera Inc. (BFRI) | 2025-12-31 | $18.08M | +2.4% |
| Septerna, Inc. (SEPN) | 2025-12-31 | $214.26M | +486.9% |
| Protagonist Therapeutics, Inc (PTGX) | 2025-12-31 | $53.48M | -23.0% |
| Gossamer Bio, Inc. (GOSS) | 2025-12-31 | $295.01M | +3.2% |
Compare XLO, INBP, CPIX, AQST side by side · Screen every company in Pharmaceutical Preparations ↗